On July 11, 2009 NATF held a open discussion on the Congressional and Senatorial Bills related to Follow-on Biosimilars. NATF's Official Statement on issues of patient safety was presented and discussed. The presentations and related material is available below.

Introduction, Video
Samuel Z. Goldhaber, MD

Introductory Remarks
Video
Jawed Fareed, PhD

Update on Heparin Contaminants and Quality Issues Surounding Unfractionated Heparin (PDF)
Video
John Fanikos, RPh, MBA

Current Issues and Statements Surrounding Biosimilars and Follow-on Biologics (PDF)
Video
Andrew Whelton, MD

Panel Discussion Video #1


Summary of United States Legislation and Proposed Bills (PDF)
Video
Craig M. Jackson , PhD

European Perspective on Biosimilars and Follow-on Biologics (PDF)
Video
Wolfram Raake, DVM


NATF's Official Position on Follow-on Biologics (PDF)
Call to Action for the Protection of Patient Safety (Video)
Craig M. Kessler, MD


Genzyme Corporation, Video
Kay Holcombe, MS



Recommendations on Biosimilar LMWHs, Video
Job Harenberg, DVM



Presentation, Video
NATT: Randy Fenninger



Panel Discussion Video #2